BRAF and melanoma: Furthermore, benzbromarone increased sensitivity of melanoma cells to BRAF inhibitor vemurafenib (Figure 9B) in A375 melanoma cells (which carries BRAF V600E mutation), suggesting that EYA1 inhibitor may be a useful therapeutic choice both as a monotherapy and as an adjunct to existing targeted melanoma therapy.